Exhale

The official blog of the Lung Institute.

New FDA Approved Drug for COPD

29 Sep 2014
| Under COPD, Lung Disease, Treatments | Posted by
| 2 Comments

The battle against chronic obstructive pulmonary disease (COPD) is a long road for those who suffer from the condition. Patients that are plagued with COPD will experience chronic coughing, shortness of breath, wheezing and recurring flare-ups. On top of that, patients have to constantly stay up-to-date with their doctor and maintain a number of treatments to relieve the symptoms of this condition.

Affecting almost 24 million people in the United States alone, COPD treatments are usually limited to oxygen support, steroid inhalers and lifestyle modifications. Since there is no cure for this disease, the main focus of treatment is to reduce the symptoms. Just recently though, a new drug has been approved by the U.S. Food and Drug Administration (FDA) to help treat patients. So what exactly is this new FDA approved drug for COPD?

What is this New FDA Approved Drug for COPD?

This new drug is called Striverdi Respimat and is available as an inhalation spray to treat patients with COPD, including chronic bronchitis and/or emphysema. Striverdi Respimat can be used once daily over a long period of time. According to the FDA, this long-acting drug helps the muscles around the airways in the lungs stay relaxed to prevent symptoms. However, it is noted that it should not be used in patients with acutely deteriorating COPD, as it can cause serious side effects, including narrowing and obstruction of the respiratory airway and cardiovascular issues.

In the same press release from the FDA, it mentions that the effectiveness and safety of Striverdi Respimat was tested in a clinical trial including 3,104 people diagnosed with COPD. People who did receive this new medication showed improved lung function compared to people who were given a placebo. Some side effects reported by people using the drug during the clinical study included runny noses, upper respiratory tract infection, bronchitis, coughing, urinary tract infection, dizziness, rash, diarrhea, back and joint pain.

The study goes on to say that the FDA warns that the drug hasn’t been tested on asthma patients at this time. More research will be needed to measure the full effects of the FDA approved drug for COPD on patients with asthma. The new drug should be available to in the United States soon to patients with this condition. Of course, if you have any questions about Striverdi Respimat, be sure to do some research or talk to your doctor about all options.

Having COPD or any other chronic illness does not have to change your life! If you or a loved one has been diagnosed with COPD and want to learn more about treatment options, please contact or call (800) 729-3065 us today.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.